US 11,738,018 B2
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
Susan Ashwell, Carlisle, MA (US); Blythe Thomson, Cincinnati, OH (US); Patrick F. Kelly, Concord, MA (US); Alan Collis, Lexington, MA (US); Jeff Davis, Hingham, MA (US); Duncan Walker, Boulder, CO (US); and Wei Lu, Newton, MA (US)
Assigned to FORMA Therapeuetics, Inc., Watertown, MA (US)
Filed by FORMA Therapeutics, Inc., Watertown, MA (US)
Filed on Apr. 28, 2021, as Appl. No. 17/243,177.
Application 17/243,177 is a continuation of application No. 16/431,588, filed on Jun. 4, 2019, granted, now 11,013,733.
Application 16/431,588 is a continuation in part of application No. PCT/US2019/032742, filed on May 16, 2019.
Application PCT/US2019/032742 is a continuation in part of application No. PCT/US2019/032747, filed on May 16, 2019.
Application 16/431,588 is a continuation in part of application No. 16/414,505, filed on May 16, 2019, granted, now 11,576,906.
Application 16/414,505 is a continuation in part of application No. 16/414,716, filed on May 16, 2019, granted, now 10,532,047.
Claims priority of provisional application 62/812,367, filed on Mar. 1, 2019.
Claims priority of provisional application 62/798,677, filed on Jan. 30, 2019.
Claims priority of provisional application 62/798,690, filed on Jan. 30, 2019.
Claims priority of provisional application 62/798,684, filed on Jan. 30, 2019.
Claims priority of provisional application 62/798,687, filed on Jan. 30, 2019.
Claims priority of provisional application 62/798,681, filed on Jan. 30, 2019.
Claims priority of provisional application 62/773,562, filed on Nov. 30, 2018.
Claims priority of provisional application 62/712,160, filed on Jul. 30, 2018.
Claims priority of provisional application 62/701,487, filed on Jul. 20, 2018.
Claims priority of provisional application 62/692,591, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,605, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,598, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,601, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,604, filed on Jun. 29, 2018.
Claims priority of provisional application 62/680,560, filed on Jun. 4, 2018.
Claims priority of provisional application 62/680,562, filed on Jun. 4, 2018.
Claims priority of provisional application 62/680,566, filed on Jun. 4, 2018.
Claims priority of provisional application 62/680,571, filed on Jun. 4, 2018.
Claims priority of provisional application 62/672,462, filed on May 16, 2018.
Claims priority of provisional application 62/672,461, filed on May 16, 2018.
Prior Publication US 2021/0244727 A1, Aug. 12, 2021
Int. Cl. A61K 31/4709 (2006.01); A61K 31/706 (2006.01); A61P 35/02 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4709 (2013.01) [A61K 31/706 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01)] 20 Claims
 
1. A method of treating an adult patient with relapsed or refractory acute myeloid leukemia having an IDH1 mutation susceptible to an IDH inhibitor as detected by an FDA-approved test, comprising the step of administering to the patient in need thereof the IDH1 inhibitor selected from Compound 1:

OG Complex Work Unit Chemistry
at a total dosage of 150 mg twice daily as a single agent until disease progression or unacceptable toxicity occurs.